All these questions and more can be answered at “Eggs to Embryos: New Techniques in the IVF Lab,” a panel presentation taking place this Sunday, September 15th from 3:30 to 4:30 PM EST at the upcoming Fertility Planit Show in NYC. I am honored and thrilled to be moderating this session that includes two top fertility experts: embryologist Joe Conaghan, Ph.D., clinical laboratory director at Pacific Fertility Center in San Francisco, and Dr. Serena Chen, director of the division of reproductive medicine in the Department of Obstetrics and Gynecology at Saint Barnabus Medical Center in Livingston, New Jersey. Auxogyn, a life sciences company focused on reproductive medicine and improving embryo selection methods, is sponsoring the presentation.
What makes this presentation particularly noteworthy is that it will focus on the many new and innovative breakthroughs that are occurring behind the scenes in the embryology/IVF laboratory, which often can seem like a mystery to fertility patients more familiar with the front office. This is an exciting time for the field, with research developing and refining innovative therapies that we hope will become game changers in the not too distant future.
This panel presentation is an opportunity to learn more and ask questions about what occurs in the embryology laboratory, from the latest advances in preparing egg and sperm for IVF, to the many new and exciting techniques available for embryo selection. It will help you understand the value and the pros and cons of these techniques and technologies as you consider your course of therapy.
Can’t make it to NYC this weekend?
Not a problem because you will be able to watch this session via streaming video, as it happens, as well as ask questions from anywhere in the world. Also it will be “live” on the Fertility Planit Website after the conference is over so you will have the opportunity to watch it at a time convenient for you.
Auxogyn, Inc, based in Menlo Park, California, is advancing the field of reproductive medicine by translating scientific discoveries in early embryo development into effective clinical tools. Auxogyn’s flagship product, the Eeva™test, is being used in Europe. It is currently pending FDA clearance and is limited to investigational use only in the U.S. However, Auxogyn is enrolling patients in clinical studies in the U.S. on an ongoing basis.
More information can be found on their websites at EevaIVF.com and Auxogyn.com